Continuing in its efforts to find a new judge for the thousands of Accutane cases pending in New Jersey state court, Hoffman-La Roche filed notice to appeal a decision by presiding Judge Carol E. Higbee not to recuse herself in the case.
The state judge overseeing Accutane mass tort litigation in New Jersey has denied Hoffmann- La Roche’s motion asking that she recuse herself.
Drug maker Hoffmann- La Roche has asked for the recusal of the New Jersey judge overseeing the Accutane mass tort litigation, asserting that Judge Carol E. Higbee is siding unfairly with plaintiffs who allege injuries from the acne drug.
Product liability plaintiffs could not show that stronger warnings for the acne drug Accutane would have prevented their injuries, the New Jersey Appellate Division has ruled.
Pharmaceutical company Hoffmann-La Roche adequately warned a user of the acne drug Accutane of the risk of developing inflammatory bowel disease, a U.S. District Court in Florida has ruled in granting summary judgment.
Drug maker Roche has appealed an $18 million jury verdict that found Accutane responsible for causing inflammatory bowel disease in two of four plaintiffs.
Published: June 7, 2012
Tags: Accutane, adverse events, Avandia, Bayer, Chantix, Coumadin, drug litigation, FDA, Food and Drug Administration, GlaxoSmithKline, Hoffman-LaRoche, Institute for Safe Medication Practices, Johnson & Johnson, Levaquin, Pfizer, Pradaxa, prescription drugs, Reglan, Wyeth, Yasmin, Yaz
The anti-nausea drug Reglan and its generic counterparts were the drugs most frequently cited in litigation in 2011, according to a consumer watchdog’s latest analysis of Food and Drug Administration statistics.
After more than a decade, the litigation against Hoffman-LaRoche, the maker of the acne drug Accutane, continues to grow.
More than 7,000 cases are currently on file in multi-district litigation consolidated in New Jersey state court, and both sides continue to vigorously litigate with no settlement negotiations in sight.
Denying a defense motion for remittitur or new trial, a New Jersey judge has affirmed a jury’s $25.16 million award to an Alabama man who suffered from inflammatory bowel disease as a result of taking the acne medication Accutane.